50 and older, any sex, with Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Ischemic Stroke Diagnostic Accuracy (CBCT Versus CT)Primary· Within 2 days after procedure
Accuracy of dual energy CBCT ASPECTS score to determine the extent and localization of ischemic stroke changes in brain tissue, evaluated by three independent neuroradiologists, using non enhanced CT ASPECTS as reference standard.
The Alberta stroke program early CT score (ASPECTS) is a 10-point quantitative topographic CT scan score used for middle cerebral artery (MCA) stroke patients. Segmental estimation of the middle cerebral artery (MCA) vascular territory is made, and 1 point is deducted from the initial score of 10 for every region involved.
Group
Value
95% CI
I - Ischemic Stroke, no Thrombectomy
90
II - Ischemic Stroke, Thrombectomy
90
Percentage of Dual Layer CBCT Images With Non-inferior Vessel Tree Visibility Compared to CTA (Reference Standard)Secondary· Within 2 days after procedure
Percentage of images made with new investigational device (dual layer CBCT) rated non-inferior vessel visibility compared to CTA (reference standard).
Vessel visibility was evaluated separately as indicators of diagnostic quality on 5-point Likert scales, adopted with slight modifications from previous studies (5: excellent vessel visibility or no artifacts, 1:vessel not visible or extensive artifacts). Sixteen intracranial arterial segments were prospectively defined for the reader study. The score difference between DL-CBCTA and CTA for each segment in each patient determined whether a segm
Group
Value
95% CI
II - Ischemic Stroke, Thrombectomy
77
Intracranial Hemorrhage Detection Accuracy (CBCT With CT as Reference Standard)Secondary· Within 2 days after procedure
Accuracy of images made with new investigational device (dual layer CBCT) to determine the presence of intracranial hemorrhage (Yes/No) using non enhanced CT as the reference standard as judged by the individual reader (neuroradiologist) through blinded reader assessment.
Group
Value
95% CI
II - Ischemic Stroke, Thrombectomy
100
III - Hemorrhagic Stroke
100
Sponsor's own description
Philips Healthcare has developed a next generation Allura investigational device. The intended purpose of the investigational device is to perform neurovascular imaging applications, including diagnostic, interventional and minimally invasive procedures on human patients. The goal of this study is to investigate the accuracy of the next generation Allura investigational device to determine the extent and localization of ischemic stroke changes in brain tissue.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06825897 — Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiograp
· NA
· recruiting
NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke
· Phase 3
· recruiting
NCT07253870 — Comperative Effects of Transcutaneous Auricular and Cervical Vagus Nerve Stimulation in Subacute Stroke Patients
· NA
· recruiting
NCT06941753 — Off-script Diagnosis & Differential Diagnosis (D&D) Training and Residents' Stroke Knowledge
· NA
· recruiting
NCT06123650 — Post Stroke Dysphagia: Effect of Adding rTMS to Conventional Therapy on the Prevalence of Pneumonia.
· NA
· recruiting
Other Philips Clinical & Medical Affairs Global trials
Trials by the same sponsor.
NCT07521735 — NEXT GEN - PHILIPS OPTIMUS
· recruiting
NCT07368036 — MR 7700 Multinuclear Application Clinical Trial
· NA
· not yet recruiting
NCT07449715 — Respiration From Pleth Validation
· recruiting
NCT07317479 — Clinical Study for P-MAR
· not yet recruiting
NCT07317427 — Precise Image for Interventional CT
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Philips Clinical & Medical Affairs Global
Last refreshed: 2 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04571099.